DexCom, Inc.  

(Public, NASDAQ:DXCM)   Watch this stock  
Find more results for Eric S. Sayers
39.05
+0.62 (1.61%)
Jul 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 37.86 - 39.29
52 week 21.76 - 49.83
Open 38.03
Vol / Avg. 763,111.00/681,281.00
Mkt cap 2.93B
P/E     -
Div/yield     -
EPS -0.43
Shares 74.92M
Beta 0.38
Inst. own 95%
Aug 6, 2014
Q2 2014 DexCom Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 6, 2014
Q2 2014 DEXCOM INC Earnings Release - 4:00PM EDT - Add to calendar
Jun 11, 2014
DEXCOM INC at William Blair & Company LLC Growth Stock Conference
Jun 3, 2014
DEXCOM INC at Jefferies Global Healthcare Conference
May 29, 2014
DEXCOM INC Annual Shareholder Meeting
May 14, 2014
DEXCOM INC at Bank of America Merrill Lynch Health Care Conference - Webcast
May 7, 2014
DEXCOM INC at Deutsche Bank Healthcare Conference - Webcast
May 1, 2014
Q1 2014 DEXCOM INC Earnings Conference Call - Webcast
May 1, 2014
Q1 2014 DEXCOM INC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -26.54% -18.62%
Operating margin -26.11% -18.06%
EBITD margin - -13.69%
Return on average assets -40.53% -26.08%
Return on average equity -57.60% -37.00%
Employees 646 -
CDP Score - -

Address

6340 Sequence Drive
SAN DIEGO, CA 92121
United States - Map
+1-858-2000200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

DexCom, Inc. (DexCom) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The Company had received approval from the United States Food and Drug Administration (FDA) for its third generation system, the SEVEN PLUS, which is designed for up to seven days of continuous use. The SEVEN PLUS is indicated for use as an adjunctive device to complement, not replace, information obtained from standard home blood glucose monitoring devices. The enabling technologies for the Company�s sensors include biomaterials, membrane systems, electrochemistry and low power microelectronics.

Officers and directors

Jonathan T. Lord M.D. Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Terrance H. Gregg Executive Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Jess Roper Chief Financial Officer, Vice President
Age: 49
Bio & Compensation  - Reuters
Kevin R. Sayer President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Steven R. Pacelli Executive Vice President - Strategy and Corporate Development
Age: 42
Bio & Compensation  - Reuters
John D. Lister Senior Vice President, General Counsel
Age: 39
Bio & Compensation  - Reuters
Richard B. Doubleday Senior Vice President - Worldwide Sales and Marketing
Age: 51
Bio & Compensation  - Reuters
Andrew K. Balo Senior Vice President - Clinical and Regulatory Affairs
Age: 66
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jeffrey C. Moy Senior Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Jorge A. Valdes Chief Technical Officer
Age: 52
Bio & Compensation  - Reuters